All Research on Biotech

Insight

Case Studies
Case Studies

Alexion Pharmaceuticals, Inc.: Focus on ultra-rare diseases as a revenue and profit driver

In 2007, Alexion gained marketing approval for Soliris, which has since become the world’s single most expensive orphan drug. This case study analyzes Alexion's success with Soliris, potential challenges, and how it is combatting these going forward.

Published By MarketLine
$495
Buy
Report
Report

The Orphan Drug Market Outlook to 2017

This report provides an analysis of the orphan drug market. It comprises brands that have gained US FDA orphan drug approval, as well as Phase III pipeline candidates that have gained an orphan drug designation from the FDA.

Published By Datamonitor
$2800
Buy
Report
Report

Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality

Datamonitor provides an overview of and profiles key hemophilia A and B pipeline products launching in the near future in the US and five major EU markets (France, Germany, Italy, Spain, and the UK).

Published By Datamonitor
$2800
Buy

View all Insight >>

Profiles

Company Profile
Company Profile

Merck & Co., Inc.

Merck & Co. (or 'the company'), known as Merck Sharp & Dohme (MSD) outside the US and Canada, is one of the leading healthcare companies in the world. The company is engaged in the research, development, manufacture and marketing of prescription pharmaceuticals, vaccines, biologic therapies, and animal health products. It is headquartered in Kenilworth, New Jersey, and employed about 70,000 people as of December 31, 2014.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

GTx, Inc.

GTx (or 'the company') is a biopharmaceutical company engaged in the development and commercialization of small molecules for the treatment of cancer and other serious medical conditions. The company operates in the US where it is headquartered in Memphis, Tennessee. GTx employed 25 people as on December 31, 2014.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

Novo Nordisk A/S

Novo Nordisk (or 'the company') is a leading global provider of diabetes products. The company also has a leadership position in hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk operates in Europe, North America, China, Japan, Korea and other regions of the world. It is headquartered in Bagsvaerd, Denmark, and employed 41,450 people as of December 31, 2014.

Published By MarketLine
$175
Buy

View all Profiles >>

No help is available.